KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests (2017 - 2025)

Historic Income from Non-Controlling Interests for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $15.8 million.

  • Amneal Pharmaceuticals' Income from Non-Controlling Interests rose 3231.76% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year increase of 3618.6%. This contributed to the annual value of $43.0 million for FY2024, which is 2194.15% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Income from Non-Controlling Interests stood at $15.8 million for Q3 2025, which was up 3231.76% from $13.2 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Income from Non-Controlling Interests' 5-year high stood at $17.8 million during Q2 2023, with a 5-year trough of -$119.3 million in Q2 2022.
  • In the last 5 years, Amneal Pharmaceuticals' Income from Non-Controlling Interests had a median value of $10.0 million in 2024 and averaged $208684.2.
  • Its Income from Non-Controlling Interests has fluctuated over the past 5 years, first crashed by 77599.75% in 2022, then surged by 503411.37% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Income from Non-Controlling Interests (Quarter) stood at -$14.1 million in 2021, then soared by 89.17% to -$1.5 million in 2022, then skyrocketed by 447.87% to $5.3 million in 2023, then skyrocketed by 94.89% to $10.3 million in 2024, then skyrocketed by 52.46% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $13.2 million for Q2 2025, and $12.4 million during Q1 2025.